US Patent 8,188,146: Claim Scope, Vascepa Patent Landscape, Expiration and Generic Risk

US Patent 8,188,146 covers a highly purified capsule formulation of ethyl eicosapentaenoic acid, commonly referred to as icosapent ethyl. The independent claims require four central elements: at least 95% ethyl-EPA, no docosahexaenoic acid, a capsule dosage form, and, in several claims, a 250 mg to 1,000 mg quantity.

The patent was historically relevant to Amarin’s Vascepa product. Its composition claims are narrower than a general EPA patent because they require specified purity, exclusion of DHA, and capsule presentation. The patent’s principal commercial value was directed to a purified EPA-only product rather than mixed EPA/DHA omega-3 formulations.

Based on the claimed priority framework and public patent records, US 8,188,146 reached the end of its ordinary patent term in December 2022. It therefore does not provide a current US blocking right against generic icosapent ethyl products. Historical Orange Book listings and related Vascepa litigation remain relevant to understanding generic entry, but they do not restore an expired patent. (FDA, 2024; USPTO, 2024)

What does US Patent 8,188,146 protect?

The patent protects pharmaceutical compositions containing highly purified ethyl-EPA in a capsule and excluding DHA. The claims focus on the product’s chemical composition and dosage form, not on a particular clinical indication.

Claim	Principal limitation	Practical scope
1	At least 95% ethyl-EPA; no DHA; capsule	Core composition claim
2	Claim 1 plus less than 3% of any other fatty acid	Higher-purity composition
3	Claim 2 plus gelatin capsule	Gelatin dosage form
4	Claims 1-3 plus 250 mg to 1,000 mg ethyl-EPA	Dosage range
5	250 mg to 1,000 mg fatty acids; at least 95% ethyl-EPA; no DHA; capsule	Independent dosage-composition claim
6	Same general composition plus less than 5% aggregate arachidonic acid and n-3 DPA; no DHA	Composition with specified impurity limits
7	Claim 5 plus less than 3% arachidonic acid	Arachidonic-acid limitation
8	Claim 6 plus less than 3% n-3 DPA	DPA limitation
9	Claim 6 plus less than 3% aggregate arachidonic acid and n-3 DPA	Tighter combined impurity limit
10	Claim 6 plus approximately 1,000 mg per capsule	High-dose capsule

The independent claims are claims 1, 5 and 6. Claims 2-4 and 7-10 narrow those independent claims.

What is the protected active ingredient?

The relevant active ingredient is ethyl eicosapentaenoic acid, also known as ethyl-EPA or icosapent ethyl. The claim language does not cover all EPA products. It requires EPA to be present in ethyl ester form and at a minimum concentration of 95% of the fatty-acid content.

A product containing triglyceride EPA, free-fatty-acid EPA, or a materially lower concentration of ethyl-EPA would not literally satisfy the central chemical limitation. A mixed EPA/DHA product would also fail the express "no docosahexaenoic acid" limitation.

Does the patent cover Lovaza or other EPA/DHA products?

No. A formulation containing DHA would not literally meet claims 1, 5 or 6 because each independent claim requires no DHA. This distinction separates the claimed product from omega-3 formulations containing both EPA and DHA, including products historically marketed as mixed EPA/DHA prescription products.

The claims also do not cover a broad class of nutritional fish-oil products merely because they contain EPA. The composition must meet the ethyl-EPA purity requirement and the capsule limitation.

How do the claims differ from one another?

Claims 1, 5 and 6 establish three overlapping but distinct claim paths.

Claim 1: purity and dosage-form protection

Claim 1 requires:

One or more fatty acids.
At least 95% of those fatty acids in the form of ethyl-EPA.
No DHA.
A capsule.

Claim 1 does not specify a quantity of ethyl-EPA. Claims 4 and 5 introduce the 250 mg to 1,000 mg range.

Claim 5: independent dose-range protection

Claim 5 independently requires 250 mg to 1,000 mg of fatty acids. At least 95% must be ethyl-EPA, DHA must be absent, and the composition must be in a capsule.

Because claim 5 is independent, invalidity or noninfringement of claim 1 would not automatically eliminate claim 5. A product could fall within claim 5 even if it did not satisfy a limitation appearing only in claim 2 or claim 3.

Claim 6: impurity-profile protection

Claim 6 requires:

At least 95% ethyl-EPA;
No DHA;
Less than 5% in aggregate of arachidonic acid and n-3 docosapentaenoic acid;
A 250 mg to 1,000 mg quantity; and
A capsule dosage form.

Claim 6 is directed to an impurity-controlled EPA composition. Claims 8 and 9 narrow the limits for n-3 DPA and the combined arachidonic-acid/n-3 DPA content.

What does "less than 3% of any fatty acid other than eicosapentaenoic acid" mean?

In claim 2, the phrase creates a stringent compositional limitation. Each non-EPA fatty acid must be below 3%, subject to the claim’s interpretation and the specification’s analytical methods. The claim is not necessarily equivalent to a requirement that all non-EPA fatty acids collectively total less than 3%.

Claims 7-9 use more specific impurity limitations. A formulation may satisfy claim 2 only if every relevant non-EPA fatty acid remains below the stated threshold. Claims 7-9 focus on specified impurities rather than every possible fatty acid.

What formulations are protected by US 8,188,146?

The patent’s strongest literal coverage is directed to a Vascepa-type softgel containing approximately 1,000 mg of highly purified icosapent ethyl and no DHA.

Formulation characteristic	Likely relationship to claims
1,000 mg icosapent ethyl softgel, at least 95% EPA ethyl ester, no DHA	Strong fit with claims 1, 5 and 6, subject to impurity data
500 mg capsule meeting the same purity requirements	Potential fit with claims 1, 5 and 6
EPA/DHA combination product	Outside the express no-DHA limitation
EPA triglyceride product	Outside the ethyl-EPA limitation
Free EPA formulation	Outside the ethyl-EPA limitation
Capsule containing less than 95% ethyl-EPA	Outside the principal composition limitation
Liquid formulation rather than capsule	Outside the express capsule limitation
Capsule with more than 1,000 mg or less than 250 mg	Potentially outside claims 4-6 and 10, but claim 1 may remain relevant if other limitations are satisfied
Capsule containing 1,000 mg total composition but less than 1,000 mg ethyl-EPA	Requires analysis of whether the claim measures total fatty acids or ethyl-EPA content

The quantity language requires careful construction. Claim 4 refers to ethyl-EPA in an amount of 250 mg to 1,000 mg. Claims 5 and 6 refer to 250 mg to 1,000 mg of fatty acids. Claim 10 refers to approximately 1,000 mg of the composition. These differences affect both infringement analysis and product design-around strategy.

When did US Patent 8,188,146 expire?

US 8,188,146 was issued on May 29, 2012. Public patent records identify a December 2022 expiration date based on the patent family’s priority and term framework. The patent is therefore no longer an enforceable US composition patent after expiration. (USPTO, 2024; Google Patents, 2024)

Event	Date
Earliest relevant priority period	2002
Patent issued	May 29, 2012
Ordinary US patent-term endpoint	December 2022
Current enforceability	Expired
Current generic blocking effect	None from this patent alone

Patent expiration is separate from historical litigation outcomes. A patent may have been asserted, listed in the Orange Book, or challenged under Paragraph IV before expiration. Those events do not extend the patent term.

Did regulatory exclusivity extend the patent?

No. FDA regulatory exclusivity and patent term are separate rights. A new chemical entity, clinical-investigation exclusivity, or other FDA exclusivity period does not automatically extend the life of a composition patent.

For Vascepa, the commercial exclusivity analysis required consideration of both Orange Book patents and FDA exclusivity. Once the relevant exclusivity periods and enforceable patent claims ended, an ANDA applicant could obtain approval if it satisfied FDA requirements.

What was the Orange Book status of US 8,188,146?

US 8,188,146 was associated with Vascepa, the prescription icosapent ethyl product marketed by Amarin. Orange Book listing status can change by supplement, product, patent declaration, or administrative update. The historical listing established a basis for Paragraph IV certification by generic applicants.

The Orange Book does not decide whether a patent is valid or infringed. It records patents submitted by the NDA holder and accepted for listing under FDA rules. Patent disputes proceed in federal court.

The relevant product-level questions were:

Whether icosapent ethyl was covered by a listed composition patent;
Whether the generic applicant made a Paragraph IV certification;
Whether the NDA holder filed an infringement action within the statutory window;
Whether the asserted patents survived validity challenges; and
Whether a settlement or court order affected approval timing.

Which companies challenged Vascepa patents?

Generic manufacturers, including Hikma Pharmaceuticals and Dr. Reddy’s Laboratories, pursued abbreviated approval pathways for generic icosapent ethyl. Amarin brought patent litigation against generic applicants in the District of Delaware and related proceedings.

The most important reported litigation involved Amarin’s asserted Vascepa patent estate and generic products approved under the ANDA pathway. In Amarin Pharma, Inc. v. Hikma Pharmaceuticals USA Inc., the Federal Circuit addressed method-of-use patent issues and upheld the district court’s findings that affected Amarin’s ability to block the generic product based on the asserted patents. (Amarin Pharma, Inc. v. Hikma Pharmaceuticals USA Inc., 2020)

The litigation was commercially significant because generic icosapent ethyl approval was not limited to the narrow triglyceride indication originally associated with Vascepa. The availability of an approved generic product materially changed the competitive environment.

What patent litigation affected icosapent ethyl generic entry?

The principal disputes involved two categories of patents:

Composition and formulation patents directed to purified ethyl-EPA products.
Method-of-use patents directed to treatment of cardiovascular risk, hypertriglyceridemia, or related patient populations.

The Federal Circuit’s decision in the Amarin-Hikma litigation narrowed the practical ability to use method-of-use patents to prevent generic sales where the generic label did not induce infringement of the asserted indication. The decision did not convert every Vascepa patent into an invalid patent, but it limited the enforceability of certain method claims against the approved generic label.

US 8,188,146 must be analyzed separately from those method-of-use patents. Its claims are composition claims. They do not require treatment of a disease, reduction of triglycerides, or prevention of cardiovascular events. Its expiration independently removed the patent from the current blocking landscape.

What is the current generic launch risk?

The risk is no longer prospective for US 8,188,146. The patent expired in 2022, and generic icosapent ethyl has entered the US market.

Risk category	Assessment
Infringement risk from US 8,188,146	No current risk based on expiration
Paragraph IV risk	Historical rather than current for this patent
ANDA approval risk	Primarily dependent on FDA requirements and remaining patents
Formulation design-around risk	Low as to this expired patent
Method-of-use patent risk	Dependent on surviving claims, labeling and induced-infringement facts
Manufacturing-process risk	Dependent on separate process patents, trade secrets and regulatory controls
Biosimilar risk	Not applicable
Generic substitution risk	High and already realized in the US

Because icosapent ethyl is a small-molecule drug, the relevant pathway is an ANDA, not a biosimilar application under the Public Health Service Act. The principal competitive risks are generic price erosion, authorized-generic strategy, formulation differentiation and residual method-of-use patent enforcement.

How strong was the patent estate for Vascepa?

US 8,188,146 had meaningful historical scope but limited present value because its term ended. Its strongest characteristics were:

Coverage of the commercial EPA-only chemical form;
A purity threshold aligned with a highly purified product;
Exclusion of DHA, which distinguished Vascepa from mixed omega-3 products;
Coverage of capsule presentations; and
Dose-range protection encompassing common commercial strengths.

Its weaknesses were equally important:

The claims were limited to capsules;
The claims required ethyl-EPA rather than EPA generally;
The claims excluded DHA and therefore did not cover combination formulations;
Purity and impurity thresholds created analytical and claim-construction issues;
The patent had a finite term ending in 2022; and
A generic manufacturer could challenge validity, noninfringement, or the scope of listed claims.

The patent was stronger as a product-specific barrier than as a platform patent. It did not broadly control all EPA therapeutics, omega-3 formulations or cardiovascular uses.

How does this patent compare with method-of-use and later formulation patents?

Patent category	What it protects	Main commercial function
US 8,188,146 composition claims	Purified ethyl-EPA capsule without DHA	Product composition
Method-of-use patents	Treatment of specified diseases or patient groups	Label and indication protection
Formulation patents	Capsule shell, excipients, stability, release or dosage presentation	Product-performance protection
Manufacturing patents	Purification, esterification, concentration or analytical control	Supply-chain barrier
Later continuation patents	Refined composition or use limitations	Potentially later expiration dates

A complete freedom-to-operate review for icosapent ethyl cannot rely on US 8,188,146 alone. It must review the full Vascepa patent family, Orange Book records, continuation patents, terminal disclaimers, patent-term adjustments, litigation judgments and any surviving claims directed to methods or manufacturing.

What licensing deals affected the commercial landscape?

The central commercial asset was Amarin’s Vascepa franchise. Amarin developed and commercialized the product and was the principal party associated with the US patent estate and related litigation. Generic companies pursued ANDA-based entry rather than biosimilar licensing.

No license is required to practice an expired patent. Any historical settlement agreement involving a generic applicant would need to be analyzed by its own effective date, launch provisions, royalty terms and scope. A settlement cannot extend the statutory term of US 8,188,146.

Key Takeaways

US 8,188,146 covers capsules containing at least 95% ethyl-EPA and no DHA.
Claims 5 and 6 add a 250 mg to 1,000 mg range and specified impurity limits.
Claim 10 focuses on an approximately 1,000 mg capsule.
The patent does not broadly cover all EPA products, EPA triglycerides, free EPA or EPA/DHA mixtures.
The patent’s commercial relevance was tied to Vascepa and highly purified icosapent ethyl.
The patent expired in December 2022 and is not a current US barrier to generic entry.
Generic icosapent ethyl products use the ANDA pathway, not the biosimilar pathway.
Current competitive analysis should focus on remaining method-of-use, formulation, manufacturing and later-family patents rather than US 8,188,146 itself.
Historical Paragraph IV litigation and Orange Book listings remain relevant to market-entry history but do not revive the expired composition claims.

FAQs

Does US 8,188,146 cover a 1,000 mg Vascepa softgel?

Historically, yes, if the product contained at least 95% ethyl-EPA, no DHA, satisfied the relevant impurity limits and was presented in a capsule. Claim 10 specifically addresses an approximately 1,000 mg capsule.

Can a generic manufacturer sell EPA with DHA under US 8,188,146?

Yes, as to this patent’s literal claims. The independent claims require no DHA. A product containing DHA would need to be evaluated against other patents, regulatory requirements and applicable labeling restrictions.

Is US 8,188,146 still listed as an enforceable Vascepa patent?

Historical Orange Book listing does not establish current enforceability. The patent expired in December 2022 and no longer supplies a current patent-term barrier.

Does a liquid icosapent ethyl product infringe the patent?

A liquid product would not literally satisfy the capsule limitation. It could still implicate other patents, including formulation, manufacturing or method-of-use patents.

Is a biosimilar application required for generic icosapent ethyl?

No. Icosapent ethyl is a small-molecule drug. Generic applicants use the ANDA pathway under section 505(j) of the Federal Food, Drug, and Cosmetic Act.

References

Amarin Pharma, Inc. v. Hikma Pharmaceuticals USA Inc., 927 F.3d 1333 (Fed. Cir. 2020).

Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services. https://www.fda.gov/drugsatfda

Google Patents. (2024). US8188146B2: Pharmaceutical compositions containing eicosapentaenoic acid. https://patents.google.com/patent/US8188146B2

United States Patent and Trademark Office. (2024). Patent Center and patent term information for US Patent No. 8,188,146. https://patentcenter.uspto.gov

U.S. Food and Drug Administration. (2024). Abbreviated new drug application process. https://www.fda.gov/drugs/types-applications/abbreviated-new-drug-application-anda

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
United Kingdom	9901809.5	Jan 27, 1999

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	300296	⤷ Start Trial
Australia	3065700	⤷ Start Trial
Brazil	0007743	⤷ Start Trial
Canada	2360776	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,188,146

Summary for Patent: 8,188,146